KMI169 is a potent and selective bisubstrate inhibitor targeting KMT9s SAM and substrate binding pockets. KMT9 monomethylates histone H4 at lysine 12 and regulates the proliferation of prostate cancer cells. KMI169 can be utilized for research in prostate cancer.
Formula:
C31H31Cl2N7O2
Target:
Epigenetic Reader Domain
* VAT and and shipping costs not included. Errors and price changes excepted
